ClinicalTrials.gg

Mania clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 167 studies for Mania across more than 10 countries. 14 are recruiting or about to start. 50 of them are mainly about Mania (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
129
Recruiting
12
Status unknown
10
Terminated
10
Withdrawn
3
Not yet recruiting
2

Phase

Phase 3
54
Phase 4
38
Phase 2
24
Phase 1
4

Where

United States
94
Ukraine
15
Poland
13
Russian Federation
11
Bulgaria
10
Canada
10

Who develops what

Add Mania to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 3 companies, 5 with this as their studies’ main aim; 3 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Bristol-Myers Squibb and Neurocrine Biosciences here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
LithiumRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06929273 · Bristol-Myers Squibb · Phase 3 · live · background · “Lithium” · registered Apr 2025
  • NCT00665366 · Otsuka Holdings Co., Ltd. · Phase 3 · background · “Lithium” · registered Apr 2008
  • NCT00266630 · Eli Lilly and Company · Phase 3 · background · “lithium” · registered Dec 2005
AstraZeneca50% of its industry studies11 study
Valproic AcidRecent, limited
Evidence
  • NCT06929273 · Bristol-Myers Squibb · Phase 3 · live · background · “Valproate” · registered Apr 2025
  • NCT00665366 · Otsuka Holdings Co., Ltd. · Phase 3 · background · “Valproate” · registered Apr 2008
  • NCT00266630 · Eli Lilly and Company · Phase 3 · background · “valproate” · registered Dec 2005
Abbott21% of its industry studiesUS: off-patent, 29 generics marketed11 study
LamotrigineRecent, limited
Evidence
  • NCT06929273 · Bristol-Myers Squibb · Phase 3 · live · background · “Lamotrigine” · registered Apr 2025
GlaxoSmithKline54% of its industry studiesUS: off-patent, 31 generics marketed11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 28 Jun 2027 est.xanomeline, trospium chloride · Bristol-Myers Squibb · Phase 3 main aimNCT07140913 A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine — primary endpoint: Change from baseline in Young Mania Rating Scale (YMRS) at Week 5 · 424 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Mania studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimuscarinics 4 open · Antipsychotics 40 · SSRIs 3

Coming up

6studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

Who these studies take

Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger. 1 (8%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (25%) take healthy volunteers.

Recruiting studies that take each age, of 12
AgeWomenMen
101 (8%)1 (8%)
1810 (83%)10 (83%)
3011 (92%)11 (92%)
4011 (92%)11 (92%)
5011 (92%)11 (92%)
6511 (92%)11 (92%)
755 (42%)5 (42%)
855 (42%)5 (42%)

Across all 167 studies, recruiting or not: 79% stop at 75 or younger and 68% at 65; 29% take children; 2% are for women only and 1% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 167. Browse all 167 → or search them.